Skip to main content
. 2023 Jul 7;13:1218206. doi: 10.3389/fonc.2023.1218206

Figure 2.

Figure 2

Action sites of anti-estrogen and CDK4/6 inhibitors: SERM and SERD bind to estrogen receptors, inhibiting downstream pathways and preventing tumor cell proliferation; CDK4/6 inhibitors prevent dividing tumor cells from the G1 phase into the S phase.